Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Oral Deucrictibant for the Prophylactic and Acute Treatment in Patients With Bradykinin Mediated Angioedema With Normal C1 Inhibitor (BK-AE-nC1INH)

NCT07046806 is registered in ClinicalTrials.gov with Institute for Asthma and Allergy as lead sponsor.

NCT NCT07046806
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07046806 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Oral Deucrictibant for the Prophylactic and Acute Treatment in Patients With Bradykinin Mediated Angioedema With Normal C1 Inhibitor (BK-AE-nC1INH)
Lead sponsor
Institute for Asthma and Allergy
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 10, 2025
Completion date
April 1, 2026
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

angioedema, bradykinin-mediated angioedema, c1 inhibitor deficiency, hereditary angioedema (hae)